Skip to main content

ARWR

Stock
Health Care
Biotechnology

Performance overview

ARWR Price
Price Chart

Forward-looking statistics

Beta
0.90
Risk
63.57%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees451
Market cap$3.0B

Fundamentals

Enterprise value$1.8B
Revenue$545.2M
Revenue per employee—
Profit margin-26.41%
Debt to equity108.23

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.24
Dividend per share—
Revenue per share$4.31
Avg trading volume (30 day)$28M
Avg trading volume (10 day)$28M
Put-call ratio—

Macro factor sensitivity

Growth+5.5
Credit+32.6
Liquidity-17.8
Inflation-3.3
Commodities+1.8
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio-3.98
Price to sales4.25
P/E Ratio-3.98
Enterprise Value to Revenue3.35
Price to book3.39

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

On CNBC's 'Mad Money Lightning Round,' Jim Cramer recommended buying Dover Corporation DOV.

Benzinga (June 4, 2025)
Growth stocks remain resilient in weakening economy, says Neuberger's Jason Tauber

Jason Tauber, Neuberger Berman large cap disciplined growth and the disruptors portfolio manager, joins 'Closing Bell: Overtime' to discus his bullish case for the growth trade.

CNBC Television (July 8, 2022)
Will Arrowhead Stock Rebound After A Large 30% Decline Last Week?

The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided to pause its early stage clinical trials for AROENaC1001, the company's investigational treatment.

Forbes (July 7, 2021)
Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?

We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.

Zacks Investment Research (February 3, 2020)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free